Arteaus Therapeutics
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Matt Kiely appointed as Genmab General Manager in the UK
Matt brings more than 20 years of global pharmaceutical leadership
FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients
One in ten children and adolescents in the US are affected by the neurological condition
AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial
Follicular lymphoma affects around 15,000 people in the US every year
Rain Free Days: A Migraine App Shaped by Real Experiences
Rain Free Days® is a free migraine support app created by Teva, 11 London, and the migraine community. It helps users track symptoms, spot patterns, and access personalised resources like...
Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer
Approximately 660,000 new cases of the disease were diagnosed globally in 2022 alone
AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma
Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US
Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer
It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year
Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition
The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours
Seagen and Genmab’s Tivdak shows promise in phase 3 cervical cancer trial
The drug received FDA accelerated approval in 2021 to treat patients with advanced disease
AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval
Approximately 150,000 new cases of DLBCL are diagnosed globally each year
Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired